UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000025335
Receipt number R000029149
Scientific Title Evaluation of HDL functions in patients with sleep apnea syndrome
Date of disclosure of the study information 2019/01/04
Last modified on 2019/12/23 15:17:38

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of HDL functions in patients with sleep apnea syndrome

Acronym

HDL functions in SAS patients

Scientific Title

Evaluation of HDL functions in patients with sleep apnea syndrome

Scientific Title:Acronym

HDL functions in SAS patients

Region

Japan


Condition

Condition

Sleep apnea syndrome

Classification by specialty

Medicine in general

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Sleep apnea syndrome (SAS) is characterized by pauses in breathing or periods of shallow breathing during sleep and associated with obesity, male gender, aging. In particular, comorbidity of obesity lead to metabolic syndrome, whereby increasing risk for cardiovascular disease (CVD). The increased risk for CVD is due to increased oxidative stress, inflammation, sympathomimetic tone, and blood pressure, together with insulin resistant. Dyslipidemia is one of major risk factors for CVD and impaired HDL function has been recently shown to be associated with CVD. In the present study, we aimed to assess HDL functions in patients with SAS

Basic objectives2

Others

Basic objectives -Others

compare various HDL functions between SAS patients and healthy controls

Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

HDL functions

Key secondary outcomes

lipids, apoproteins


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

AHI 15 or greater

Key exclusion criteria

1) HbA1c >10%
2) recent cerebrovascular events (6 months)
3) liver dysfunction (AST/ALT greater than 3 fold of upper normal limits)
4) advanced renal inssuficiency including hemodialysis
5) heart failure (NYHA III/IV)
6) cancer or critically ill patients
7) pregnant women
8) serious infection
9) subjects to whom attending doctor judges inappropriate to join the study

Target sample size

140


Research contact person

Name of lead principal investigator

1st name Katsunori
Middle name
Last name Ikewaki

Organization

National defense medical college

Division name

Division of anti-aging, and vascular medicine

Zip code

359-8513

Address

3-2 Namiki Tokorozawa Saitama

TEL

0429-95-1211

Email

kikewaki@hotmail.com


Public contact

Name of contact person

1st name Katsunori
Middle name
Last name Ikewaki

Organization

National defense medical college

Division name

Division of anti-aging, and vascular medicine

Zip code

359-8513

Address

3-2 Namiki Tokorozawa Saitama

TEL

0429-95-1211

Homepage URL


Email

kikewaki@hotmail.com


Sponsor or person

Institute

National Defense Medical College

Institute

Department

Personal name



Funding Source

Organization

National Defense Medical College

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

National defense medical college

Address

3-2 Namiki Tokorozawa Saitama

Tel

0429-95-1211

Email

kikewaki@hotmail.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

防衛医科大学校(埼玉県) 抗加齢血管内科、耳鼻咽喉科学講座
睡眠総合ケアクリニック代々木(東京都)


Other administrative information

Date of disclosure of the study information

2019 Year 01 Month 04 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2016 Year 12 Month 20 Day

Date of IRB

2017 Year 01 Month 11 Day

Anticipated trial start date

2017 Year 04 Month 20 Day

Last follow-up date

2019 Year 05 Month 29 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

case control study
case SAS patients n=80
controls non-SAS n=60


Management information

Registered date

2016 Year 12 Month 20 Day

Last modified on

2019 Year 12 Month 23 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029149


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name